|
& |
And |
|
|
ΔMS |
Change in mental status |
|
|
1° |
Primary |
|
|
2° |
Secondary |
|
|
3DCRT |
3D conformal Radiotherapy |
|
|
5-FU |
5-fluorouracil |
|
|
6-MP |
6-mercaptopurine |
|
|
Aϕ |
Alkaline phosphatase |
|
|
a/w |
Associated with |
|
|
AA |
African-american |
|
|
AASLD |
American Association for Study of Liver Diseases |
|
|
Ab |
Antibody |
|
|
ABC |
Activated B-cell |
|
|
abd wall |
Abdominal wall |
|
|
abnl |
Abnormal |
|
|
ABVD |
Doxorubicin, bleomycin, vinblastine, dacarbazine |
|
|
ABW |
Actual body weight |
|
|
abx |
Antibiotics |
|
|
AC |
Assist control |
|
|
ACC |
Adrenal cortex carcinomas |
|
|
ACL |
Anticardiolipin antibody |
|
|
ACS |
Acute coronary syndrome |
|
|
ACT |
Adoptive cell therapy |
|
|
ACTH |
Adrenocorticotropic hormone |
|
|
ACV |
Acyclovir |
|
|
ADA |
Adenosine deaminase |
|
|
ADCC |
Antibody-dependent cellular cytotoxicity |
|
|
ADCL |
Adenocarcinoma of the lung |
|
|
ADH |
Antidiuretic hormone |
|
|
ADSQLC |
Adenosquamous cell lung cancer |
|
|
ADT |
Androgen deprivation therapy |
|
|
adv |
Advanced |
|
|
AEs |
Adverse events |
|
|
AF |
Atrial fibrillation |
|
|
AFB |
Acid-fast bacilli |
|
|
AFP |
α-fetoprotein |
|
|
AG |
Aminoglycoside |
|
|
Ag |
Antigen |
|
|
AICARFT |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase |
|
|
AIDS |
Acquired immunodeficiency syndrome |
|
|
AIHA |
Autoimmune hemolytic anemia |
|
|
AIM |
Doxorubicin, ifofsamide, mesna |
|
|
AIIR |
Airborne infection isolation room |
|
|
AIN |
Acute interstitial nephritis |
|
|
AIN |
Anal intraepithelial neoplasia |
|
|
AIP |
Acute intermittent porphyria |
|
|
AITL |
Angioimmunoblastic T cell lymphoma |
|
|
AJ |
Ashkenazi Jewish |
|
|
AJCC |
American Joint Committee on Cancer |
|
|
AKI |
Acute kidney injury |
|
|
ALA |
Aminolevulinic acid |
|
|
ALC |
Absolute lymphocyte count |
|
|
ALCL |
Anaplastic large-cell lymphoma |
|
|
ALK |
Anaplastic lymphoma kinase |
|
|
ALL |
Acute lymphoblastic leukemia |
|
|
ALT |
Alanine aminotransferase |
|
|
AML |
Acute myelogenous leukemia |
|
|
amp |
Amplification |
|
|
ANC |
Absolute neutrophil count |
|
|
angio |
Angiogram |
|
|
AOCI |
Anemia of chronic inflammation |
|
|
APC |
Activated protein C |
|
|
APL |
Acute promyeloctic leukemia |
|
|
APLA |
Antiphospholipid antibody |
|
|
APR |
Abdominal perineal resection |
|
|
APS |
Antiphospholipid antibody syndrome |
|
|
ara-CTP |
Arabinofuranosylcytosine triphosphate |
|
|
ARDS |
Acute respiratory distress syndrome |
|
|
ASA |
Aspirin |
|
|
ASCR |
Autologous stem cell rescue |
|
|
ASCT |
Autologous stem cell transplantation |
|
|
ASM |
Aggressive systemic mastocytosis |
|
|
AST |
Aspartate aminotransferase |
|
|
asx |
Asymptomatic |
|
|
AT |
Accelerated titration |
|
|
ATG |
Antithymocyte globulin |
|
|
ATIII |
Antithrombin III |
|
|
ATLL |
Adult T cell lymphoma and leukemia |
|
|
ATO |
Arsenic trioxide |
|
|
ATRA |
All-trans-retinoic acid |
|
|
AV |
Atrioventricular |
|
|
Avg |
Average |
|
|
AVN |
Avascular necrosis |
|
|
AZA |
Azathioprine |
|
|
B2M |
β2-microglobulin |
|
|
b/c |
Because |
|
|
BAC |
Bronchioloalveolar carcinoma |
|
|
BBB |
Bundle branch block |
|
|
BBW |
black box warning |
|
|
BC |
Breast cancer |
|
|
BCC |
Basal cell carcinoma |
|
|
BCLC |
Barcelona-Clιnic Liver Cancer |
|
|
BCR |
B cell receptors |
|
|
BCS |
Breast-conserving surgery |
|
|
BCx |
Blood culture |
|
|
BD |
Bile duct |
|
|
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, & prednisone |
||
|
BER |
Base-excision repair |
|
|
Bev |
Bevacizumab |
|
|
bili. |
Bilirubin |
|
|
BiV |
Biventricular |
|
|
BM |
Bone marrow |
|
|
Bowel movement |
||
|
BMA |
Bone-modifying agents |
|
|
BMD |
Bone mineral density |
|
|
BMI |
Body mass index |
|
|
BMP |
Basic metabolic profile |
|
|
BMT |
Bone marrow transplant |
|
|
BOOP |
Bronchiolitis obliterans with organizing pneumonia |
|
|
bp |
Base pairs |
|
|
BP |
Blood pressure |
|
|
BPT |
Bleomycin pulmonary toxicity |
|
|
BS |
Breath sounds |
|
|
BSC |
Best supportive care |
|
|
BTA |
Bladder tumor antigen |
|
|
BUN |
Blood urea nitrogen |
|
|
BW |
Body weight |
|
|
bx |
Biopsy |
|
|
c/w |
Compared with |
|
|
Consistent with |
||
|
C′ |
Complement |
|
|
CA |
Cancer |
|
|
CAD |
Coronary artery disease |
|
|
CAF |
Cyclophosphamide/doxorubicin/fluorouracil |
|
|
Cap |
Capecitabine |
|
|
CAPD |
Chronic ambulatory peritoneal dialysis |
|
|
CAR |
Chimeric antigen receptor |
|
|
CAV |
Cyclophosphamide, adriamycin (doxorubicin), vincristine |
|
|
CBC |
Complete blood count |
|
|
CBD |
Common bile duct |
|
|
CBE |
Clinical breast exam |
|
|
CBF |
Core-binding factor |
|
|
CC |
Cholangiocarcinomas |
|
|
CCND1 |
Cyclin D1 |
|
|
ccRCC |
Clear cell renal cell cancer/clear cell renal cell carcinoma |
|
|
CCY |
Cholecystectomy |
|
|
CD |
Crohn disease |
|
|
CDI |
Clostridium difficile Infection |
|
|
CDKs |
Cyclin-dependent kinases |
|
|
CEA |
Carcinoembryonic antigen |
|
|
Carotid endarterectomy |
||
|
CEP |
Congenital erythropoietic porphyria |
|
|
ceph. |
Cephalosporin |
|
|
Cftx |
Ceftriaxone |
|
|
CFU |
Colony forming units |
|
|
CgA |
Chromogranin A |
|
|
CHF |
Congestive heart failure |
|
|
ChIP |
Chromatin ImmunoPrecipitation |
|
|
CHOEP |
CHOP plus etoposide |
|
|
CHOP |
Cyclophosphamide, doxorubicin, vincristine & prednisone |
|
|
CHR |
Complete hematologic response |
|
|
CI |
Cardiac index |
|
|
CIMP |
CpG island methylator phenotype |
|
|
CIN |
Cervical intraepithelial neoplasia |
|
|
CIS |
Cisplatin |
|
|
CK |
Cytokeratin |
|
|
CKD |
Chronic kidney disease |
|
|
CLIA |
Clinical Laboratory Improvement Amendments |
|
|
CLL |
Chronic lymphocytic leukemia |
|
|
CLPs |
Common lymphoid progenitors |
|
|
CML |
Chronic myelogenous leukemia |
|
|
CMML |
Chronic myelomonocytic leukemia |
|
|
CMP |
Cardiomyopathy |
|
|
Common myeloid progenitor |
||
|
CMT |
Combined modality treatment |
|
|
CMV |
Cytomegalovirus |
|
|
CN |
Cranial nerve |
|
|
CNS |
Central nervous system |
|
|
COG |
Children’s Oncology Group |
|
|
conc. |
Concentration |
|
|
COPD |
Chronic obstructive pulmonary disease |
|
|
CP |
Chest pain |
|
|
CR |
Complete response |
|
|
Cr |
Creatinine |
|
|
CRBSI |
Catheter-related Bloodstream Infection |
|
|
CRC |
Colorectal cancer |
|
|
CrCl |
Creatinine clearance |
|
|
CRI |
Chronic renal insufficiency |
|
|
CRM |
Circumferential resection margin |
|
|
CRM |
Continual reassessment method |
|
|
CRP |
C-reactive protein |
|
|
CRPC |
Castration-resistant prostate cancer |
|
|
CsA |
Cyclosporine A |
|
|
CSF |
Cerebrospinal fluid |
|
|
CT |
Computed tomogram |
|
|
CTCL |
Cutaneous T-cell lymphoma |
|
|
CTD |
Connective tissue disease |
|
|
CTEP |
Cancer Therapy Evaluation Program |
|
|
CTL |
Cytotoxic T cell |
|
|
CUP |
Cancer of Unknown Primary |
|
|
CV |
Cardiovascular |
|
|
CVA |
Cerebrovascular accident |
|
|
CVAD |
Cyclophosphamide, vincristine, doxorubicin, and dexamethasone |
|
|
Central venous pressure |
||
|
CVT |
Cisplatin, vinblastine, temozolomide |
|
|
CW |
Chest wall |
|
|
cx |
Culture |
|
|
CXR |
Chest radiograph |
|
|
d |
Day |
|
|
d/c |
Discontinue |
|
|
DA |
Dopamine |
|
|
DAT |
Direct antiglobulin test |
|
|
DBP |
Diastolic blood pressure |
|
|
DC |
Dendritic Cell |
|
|
Docetaxel and cyclophosphamide |
||
|
DDI |
Drug-drug interactions |
|
|
ddNTP |
Dideoxynucleotide triphosphates |
|
|
Ddx |
Differential diagnosis |
|
|
DES |
Drug-eluting stent |
|
|
Des-gamma-carboxyprothrombin |
||
|
DFS |
Disease-free survival |
|
|
DHAP |
Dexamethasone, cytarabine, CIS |
|
|
DHEA |
Dehydroepiandrosterone |
|
|
DHFR |
Dihydrofolate reductase |
|
|
DHTR |
Delayed Hemolytic Transfusion Reaction |
|
|
DI |
Diabetes insipidus |
|
|
DIC |
Disseminated intravascular coagulation |
|
|
diff. |
Differential |
|
|
DIPSS |
Dynamic IPSS |
|
|
DKA |
Diabetic ketoacidosis |
|
|
DLBCL |
Diffuse large B-cell lymphoma |
|
|
DLCO |
Diffusion capacity of the lung |
|
|
DLI |
Donor lymphocyte infusion |
|
|
DLT |
Dose-limiting toxicity |
|
|
DM |
Dermatomyositis |
|
|
Diabetes mellitus |
||
|
DNMT |
DNA methyltransferase |
|
|
dNTPs |
Deoxynucleotide triphosphates |
|
|
DOE |
Dyspnea on exertion |
|
|
DPD |
Dihydropyrimidine dehydrogenase |
|
|
DRE |
Digital rectal exam |
|
|
DS |
Durie-Salmon |
|
|
DTIC |
Dacarbazine |
|
|
DSBs |
Double strand breaks |
|
|
DSMB |
Data safety monitoring board |
|
|
DSNB |
Dynamic sentinel node biopsy |
|
|
DVT |
Deep vein thrombosis |
|
|
dx |
Diagnosis |
|
|
dz |
Disease |
|
|
EBRT |
External beam radiation therapy |
|
|
EBUS |
Endobronchial US |
|
|
EBV |
Epstein-Barr virus |
|
|
ECF |
Epirubicin, CIS, 5-FU |
|
|
ECG |
Electrocardiogram |
|
|
echo |
Echocardiogram |
|
|
ECX |
Epirubicin, CIS, Cap |
|
|
EF |
Ejection fraction |
|
|
EFS |
Event-free survival |
|
|
EGD |
Esophagogastroduodenoscopy |
|
|
EGFR |
Epidermal growth factor receptor |
|
|
EGJ |
Esophagogastric junction |
|
|
ELISA |
Enzyme-linked immunosorbent assay |
|
|
EM |
Electron microscopy |
|
|
EMT |
Epithelial-to-mesenchymal transition |
|
|
ENETS |
European Neuroendocrine Tumor Society |
|
|
ENMZL |
Extranodal marginal zone lymphoma |
|
|
EOD |
Extent of disease |
|
|
EOX |
Epirubicin, OX, Cap |
|
|
EPIC |
Early postoperative intraperitoneal chemotherapy |
|
|
Epo |
Erythropoietin |
|
|
EPP |
Extrapleural pneumonectomy |
|
|
Erythropoietic protoporphyria |
||
|
ER |
Estrogen receptor |
|
|
ERCP |
Endoscopic retrograde cholangiopancreatography |
|
|
ERSPC |
European Randomized Study of Screening for Prostate Cancer |
|
|
ESAs |
Erythropoiesis-stimulating agents |
|
|
ESBL |
Extended spectrum beta-lactamase |
|
|
ESCC |
Epidural spinal cord compression scale |
|
|
ESFT |
Ewing sarcoma family of tumors |
|
|
ESP |
End-systolic pressure |
|
|
ESR |
Erythrocyte sedimentation rate |
|
|
ESRD |
End-stage renal disease |
|
|
ET |
Essential thrombocythemia |
|
|
ETT |
Endotracheal tube |
|
|
EtOH |
Alcohol |
|
|
EUS |
Endoscopic ultrasound |
|
|
FAD |
Food and drug administration |
|
|
FAMMM |
Familial atypical multiple mole melanoma syndrome |
|
|
FAP |
Familial adenomatous polyposis |
|
|
FDG |
Fluorodeoxyglucose |
|
|
FDR |
False Discovery Rate |
|
|
FDUMP |
5-fluorodeoxyuridine monophosphate |
|
|
FEV1 |
Forced expiratory volume in 1 second |
|
|
FFP |
Fresh frozen plasma |
|
|
FFTF |
Freedom from treatment failure |
|
|
FGFR |
Fibroblast growth factor receptor |
|
|
Family history |
||
|
FISH |
Fluorescent in situ hybridizations |
|
|
FL |
Follicular lymphoma |
|
|
FLC |
Free light chain |
|
|
FMTC |
Familial medullary thyroid CA |
|
|
FMTC |
Familial medullary thyroid carcinoma |
|
|
FN |
False negative/false – |
|
|
FNA |
Fine needle aspiration |
|
|
FOBT |
Fecal occult blood testing |
|
|
FP |
False positive/false + |
|
|
FQ |
Fluoroquinolone |
|
|
FSC |
Forward scatter |
|
|
FSH |
Follicle stimulating hormone |
|
|
FUO |
Fever of unknown origin |
|
|
FVC |
Forced vital capacity |
|
|
G6PD |
Glucose-6-phosphate dehydrogenase |
|
|
GARFT |
glycinamide ribonucleotide formyltransferase |
|
|
GB |
Gallbladder |
|
|
GBC |
Gallbladder cancer |
|
|
GBM |
Glomerular basement membrane |
|
|
GC |
Gemcitabine, cisplatin |
|
|
GCB |
Germinal Center B-cell |
|
|
GCP |
Good clinical practice |
|
|
G-CSF |
Granulocyte colony stimulating factor |
|
|
GCT |
Germ cell tumor |
|
|
GE |
Gastroesophageal |
|
|
GEJ |
Gastroesophageal junction |
|
|
GELF |
Groupe d’Etude des Lymphomes Folliculaires |
|
|
GEM |
Gemcitabine |
|
|
gen. |
Generation |
|
|
GERD |
Gastroesophageal reflux disease |
|
|
GFR |
Glomerular filtration rate |
|
|
GGT |
γ-glutamyl transpeptidase |
|
|
GH |
Growth hormone |
|
|
GI |
Gastrointestinal |
|
|
GIB |
Gastrointestinal bleed |
|
|
GIST |
Gastrointestinal stromal tumor |
|
|
glc |
Glucose |
|
|
GM1 |
Ganglioside M1 |
|
|
GM-CSF |
Granulocyte-macrophage colony-stimulating factor |
|
|
GNR |
Gram negative rods |
|
|
GnRH |
Gonadotropin releasing hormone |
|
|
GOC |
Goals of care |
|
|
GPA |
Graded Prognostic Assessment |
|
|
GPC |
Gram positive cocci |
|
|
GTN |
Gestational trophoblastic neoplasia |
|
|
GU |
Gastric ulcer |
|
|
GVHD |
Graft-versus-host disease |
|
|
h |
Hour |
|
|
h/o |
History of |
|
|
H2RA |
H2-receptor antagonist |
|
|
HA |
Headache |
|
|
HAART |
Highly active antiretroviral therapy |
|
|
HAV |
Hepatitis A virus |
|
|
Hb |
Hemoglobin |
|
|
HBV |
Hepatitis B virus |
|
|
HCC |
Hepatocellular carcinoma |
|
|
hCG |
Human chorionic gonadotropin |
|
|
HCL |
Hairy cell leukemia |
|
|
HCP |
Hereditary coproporphyria |
|
|
Hct |
Hematocrit |
|
|
HCT-CI |
Hematopoietic Cell Transplantation-Specific Comorbidity Index |
|
|
HCV |
Hepatitis C virus |
|
|
HD |
Hemodialysis |
|
|
HDAC |
Histone deacetylase |
|
|
HDC |
High-dose chemotherapy |
|
|
HD-MTX |
High-dose methotrexate |
|
|
HDT |
High-dose therapy |
|
|
HE |
Hereditary Elliptocytosis |
|
|
HE-4 |
Human epididymis protein 4 |
|
|
HELLP |
Hemolysis, abnormal LFTs, low platelets |
|
|
HELP |
HpaII tiny fragment Enrichment by Ligation-mediated PCR |
|
|
HEP |
Hepatoerythropoietic Porphyria |
|
|
HF |
Heart failure |
|
|
HFS |
Hand-foot syndrome |
|
|
HGS |
High-grade serous |
|
|
HIF |
Hypoxia-inducible factor |
|
|
HIPAA |
Health Insurance Portability and Accountability Act |
|
|
HIPEC |
Hyperthermic intraperitoneal chemotherapy |
|
|
HIT |
Heparin-induced thrombocytopenia |
|
|
HITT |
Heparin-induced Thrombocytopenia and Thrombosis |
|
|
HIV |
Human immunodeficiency virus |
|
|
HL |
Hodgkin lymphoma |
|
|
HLA |
Human leukocyte antigen |
|
|
HMP |
Hexose Monophosphate |
|
|
HNPCC |
Hereditary nonpolyposis colorectal cancer |
|
|
HNSCC |
Head and neck squamous cell carcinoma |
|
|
HoTN |
Hypotension |
|
|
hpf |
High power field |
|
|
HPP |
Hereditary pyropoikilocytosis |
|
|
HPT |
Hyperparathyroidism |
|
|
HPV |
Human papillomavirus |
|
|
HR |
Hazard Ratio |
|
|
HR |
Heart rate |
|
|
HR |
Homologous recombination |
|
|
HRT |
Hormone replacement therapy |
|
|
HS |
Hereditary spherocytosis |
|
|
HSC |
Hematopoietic stem cell |
|
|
Hematopoietic stem cell transplantation |
||
|
HSIL |
High-grade squamous intraepithelial |
|
|
HSM |
Hepatosplenomegaly |
|
|
HSR |
Hypersensitivity reaction |
|
|
HSV |
Herpes simplex virus |
|
|
HTLV-1 |
Human T-lymphotropic virus |
|
|
HTN |
Hypertension |
|
|
HUS |
Hemolytic uremic syndrome |
|
|
hx |
History |
|
|
IABP |
Intra-aortic balloon pump |
|
|
IAP |
Inhibitor of apoptosis |
|
|
IBD |
Inflammatory bowel disease |
|
|
IBW |
Ideal body weight |
|
|
ICE |
Ifosfamide, carboplatin, etoposide |
|
|
ICH |
International conference on harmonization |
|
|
ICH |
Intracranial hemorrhage |
|
|
ICOS |
Inducible costimulator |
|
|
ICP |
Intracranial pressure |
|
|
ICU |
Intensive care unit |
|
|
IDC |
Invasive ductal carcinoma |
|
|
IDO |
Indoleamine 2,3-dioxygenase |
|
|
IDT |
Interdisciplinary team |
|
|
IE |
Ifosfamide + etoposide |
|
|
IE |
Infective endocarditis |
|
|
IF |
Intrinsic factor |
|
|
IFE |
Immunofixation electrophoresis |
|
|
IFN |
Interferon |
|
|
IFRT |
Involved-field radiotherapy |
|
|
Ig |
Immunoglobulin |
|
|
IGCCCG |
International Germ Cell Cancer Collaborative Group |
|
|
IGF |
Insulin-like growth factor |
|
|
IGRT |
Image-guided radiation therapy |
|
|
IHC |
Immunohistochemistry |
|
|
IHH |
Indian Hedgehog |
|
|
IITs |
Investigator-initiated trials |
|
|
ILC |
Invasive lobular carcinoma |
|
|
IMIG |
International Mesothelioma Interest Group |
|
|
IMRT |
Image-guided intensity-modulated RT |
|
|
IND |
Investigational new drug |
|
|
info |
Information |
|
|
infxn |
Infection |
|
|
inh |
Inhaled |
|
|
INH |
Isoniazid |
|
|
inj |
Injection |
|
|
INR |
International normalized ratio |
|
|
IORT |
Intraoperative radiation therapy |
|
|
IPHC |
Intraperitoneal heated chemotherapy |
|
|
IPI |
International Prognostic Index |
|
|
IPS |
International Prognostic Score |
|
|
IPSS |
International Prognostic Scoring System |
|
|
IR |
Ionizing Radiation |
|
|
irAEs |
Immune-related adverse events |
|
|
IRB |
Institutional review board |
|
|
irRC |
Immune-related response criteria |
|
|
IS |
International Scale |
|
|
ISM |
Indolent systemic mastocytosis |
|
|
ISRT |
Involved Site Radiation Therapy |
|
|
ISS |
International Staging System |
|
|
ISTs |
Industry-sponsored trials |
|
|
IT |
Intrathecal |
|
|
ITP |
Idiopathic thrombocytopenic purpura |
|
|
IV |
Intravenous |
|
|
IVB |
Intravenous bolus |
|
|
IVC |
Inferior vena cava |
|
|
IVF |
Intravenous fluids |
|
|
IVIg |
Intravenous immunoglobulin |
|
|
IVP |
Intravenous push |
|
|
jxn |
Junction |
|
|
KIRs |
Killer immunoglobulin-like receptors |
|
|
KPC |
Klebsiella pneumoniae carbapenemase |
|
|
LA |
Long-acting |
|
|
Lupus anticoagulant |
||
|
LAD |
Left anterior descending coronary artery |
|
|
Left axis deviation |
||
|
LAN |
Lymphadenopathy |
|
|
LBL |
Acute lymphoblastic lymphoma |
|
|
LCA |
Left coronary artery |
|
|
LCA |
Leukocyte common Antigen |
|
|
LDCT |
Low-dose computed tomography |
|
|
LDH |
Lactate dehydrogenase |
|
|
LDR |
Low–dose–rate |
|
|
LE |
Lower extremity |
|
|
LEEP |
Loop electrical excision procedure |
|
|
LFS |
Li–fraumeni syndrome |
|
|
LFTs |
Liver function tests |
|
|
LGRs |
Large genomic rearrangements |
|
|
LH |
Luteinizing hormone |
|
|
LHRH |
Luteinizing-hormone-releasing hormone |
|
|
LINACs |
Linear accelerators |
|
|
LMWH |
Low-molecular-weight heparin |
|
|
LN |
Lymph node |
|
|
LND |
Lymph node dissection |
|
|
LOH |
Loss of heterozygosity |
|
|
LP |
Lumbar puncture |
|
|
LPL |
Lymphoplasmacytic lymphoma |
|
|
Lynch Syndrome |
||
|
LV |
Left ventricle |
|
|
LVEF |
Left ventricular ejection fraction |
|
|
LVI |
Lymphovascular invasion |
|
|
LVSI |
Lymphovascular space invasion |
|
|
Mϕ |
Macrophage |
|
|
MAG |
Myelin-associated glycoprotein |
|
|
MAHA |
Microangiopathic hemolytic anemia |
|
|
MALT |
Mucosa-associated lymphoid tissue |
|
|
MAO |
Monoamine oxidase |
|
|
MAP |
Mean arterial pressure |
|
|
MAP |
MYH-Associated Polyposis |
|
|
MAPK |
Mitogen-activated protein kinase |
|
|
MBC |
Metastatic breast cancer |
|
|
MCL |
Mast cell leukemia |
|
|
Mantle cell lymphoma |
||
|
MCV |
Mean corpuscular volume |
|
|
MDR-1 |
Multi-drug resistance 1 |
|
|
MDRO |
Multi-drug resistant organism |
|
|
MDS |
Myelodysplastic syndrome |
|
|
MDSC |
Myeloid-derived suppressor cells |
|
|
MED |
Minimum efficacious dose |
|
|
MEN |
Multiple endocrine neoplasia |
|
|
met |
Metastasis/metastatic |
|
|
mets |
Metastases |
|
|
MF |
Mycosis fungoides |
|
|
MF |
Myelofibrosis |
|
|
MFH |
Malignant fibrous histiocytoma |
|
|
MG |
Myasthenia gravis |
|
|
mgmt |
Management |
|
|
MGMT |
Methyl guanine methyltransferase |
|
|
MGUS |
Monoclonal gammopathy of undetermined significance |
|
|
MHC |
Major histocompatibility complex |
|
|
MI |
Myocardial infarction |
|
|
min |
Minute |
|
|
min. |
Minimal |
|
|
MIPI |
Mantle Cell IPI |
|
|
MIS |
Microsatellite instability |
|
|
MM |
Multiple myeloma |
|
|
MMA |
Methylmalonic acid |
|
|
MMC |
Mitomycin C |
|
|
MMF |
Mycophenolate mofetil |
|
|
MMR |
Mismatch repair |
|
|
MN |
Membranous nephropathy |
|
|
MNZ |
Metronidazole |
|
|
MOA |
Mechanism of action |
|
|
mod. |
Moderate |
|
|
mos |
Months |
|
|
MPGN |
Membranoproliferative glomerulonephritis |
|
|
MPN |
Myeloproliferative neoplasm |
|
|
MR |
Magnetic resonance |
|
|
Mitral regurgitation |
||
|
MRCP |
Magnetic resonance cholangiopancreatography |
|
|
MRI |
Magnetic resonance imaging |
|
|
MRSA |
Methicillin-resistant S. aureus |
|
|
MS |
Mitral stenosis |
|
|
MSI |
Microsatellite instability |
|
|
MSKCC |
Memorial Sloan–Kettering Cancer Center |
|
|
MSSA |
Methicillin-Sensitive Staphylococcus aureus |
|
|
MSTS |
Metastatic soft tissue sarcoma |
|
|
Mt |
Mutation |
|
|
MTb |
Mycobacterium tuberculosis |
|
|
MTC |
Medullary thyroid CA |
|
|
MTD |
Maximum-tolerated dose |
|
|
MTHFR |
Methylenetetrahydrofolate reductase |
|
|
mTOR |
Mammalian target of rapamycin |
|
|
MTP |
Metatarsal phalangeal (joint) |
|
|
MTX |
Methotrexate |
|
|
MUD |
Matched unrelated donor |
|
|
MUGA |
Multi gated acquisition scan |
|
|
MVAC |
Methotrexate, vinblastine, doxorubicin, cisplatin |
|
|
MZL |
Marginal zone lymphoma |
|
|
N/V |
Nausea and/or vomiting |
|
|
NASH |
Non-alcoholic steatohepatitis |
|
|
NB-UVB |
Narrowband ultraviolet B |
|
|
NCCN |
National comprehensive cancer network |
|
|
NCI |
National cancer institute |
|
|
NDA |
New drug application |
|
|
NDV |
Newcastle Disease Virus |
|
|
NEC |
Neuroendocrine carcinoma |
|
|
NED |
No evidence of disease |
|
|
Neoadj |
Neoadjuvant |
|
|
NER |
Nucleotide excision repair |
|
|
NETs |
Neuroendocrine tumors |
|
|
NG |
Nasogastric |
|
|
NGS |
Next generation sequencing |
|
|
NGT |
Nasogastric tube |
|
|
NHEJ |
Nonhomologous end joining |
|
|
NHL |
Non-Hodgkinlymphoma |
|
|
NK |
Natural killer |
|
|
nl |
Normal |
|
|
NLPHL |
Nodular Lymphocyte Predominant Hodgkin Lymphoma |
|
|
NM |
Neuromuscular |
|
|
NMP22 |
Nuclear matrix protein 22 |
|
|
NNT |
Number needed to treat |
|
|
NO |
Nitric oxide |
|
|
NR |
Not reported |
|
|
NS |
Normal saline |
|
|
NSAID |
Nonsteroidal anti-inflammatory drug |
|
|
NSCLC |
Non-small cell lung cancer |
|
|
NSE |
Neuron specific enolase |
|
|
Nonseminomatous germ cell tumors |
||
|
NuRD |
Nucleosome remodelling & histone deacetylase |
|
|
NVE |
Native valve endocarditis |
|
|
NYHA |
New York Heart Association |
|
|
O/D |
Overdose |
|
|
o/w |
Otherwise |
|
|
OBD |
Optimal biologic dose/optimum biologic dose |
|
|
OCP |
Oral contraceptive pill |
|
|
OGCT |
Ovarian germ cell tumor |
|
|
ONJ |
Osteonecrosis of jaw |
|
|
OR |
Odds ratio |
|
|
ORR |
Objective response rate or overall response rate |
|
|
OS |
Overall survival |
|
|
OV |
Oncolytic viruses |
|
|
OX |
Oxaliplatin |
|
|
P/D |
Pleurectomy/decortication |
|
|
p/w |
Present(s) with |
|
|
PA |
Pulmonary artery |
|
|
PanIN |
Pancreatic intraepithelial neoplasia |
|
|
PAP |
Prostatic acid phosphatase |
|
|
PARP |
Poly ADP ribose polymerase |
|
|
PARP |
Poly (ADP-ribose) polymerase |
|
|
pb |
Problem |
|
|
PBGD |
Porphobilinogen deaminase |
|
|
PBMC |
Peripheral blood mononuclear cells |
|
|
PC |
Prostate cancer |
|
|
Plasma cell |
||
|
PCA |
Principle components analysis |
|
|
PCALCL |
Primary cutaneous ALCL |
|
|
PCI |
Prophylactic Cranial Irradiation |
|
|
PCL |
Primary CNS lymphoma |
|
|
PCN |
Penicillin |
|
|
PCNA |
Proliferating cell nuclear antigen |
|
|
PCNSLs |
Primary CNS lymphomas |
|
|
PCOS |
Polycystic Ovary Syndrome |
|
|
PCP |
Pneumocystis jiroveci pneumonia |
|
|
pCR |
Pathologic complete response |
|
|
PCR |
Polymerase chain reaction |
|
|
PCT |
Porphyria cutanea tarda |
|
|
PCV |
Polycythemia vera |
|
|
Procarbazine, Lomustine, Vincristine |
||
|
PD |
Parkinson’s disease |
|
|
Pharmacodynamics |
||
|
Peritoneal dialysis |
||
|
PDGF |
Platelet-derived growth factor |
|
|
PDGFR |
Platelet-derived growth factor receptor |
|
|
PDT |
Photodynamic therapy |
|
|
PE |
Pulmonary embolism |
|
|
peme |
Pemetrexed |
|
|
PET |
Positron emission tomography |
|
|
PEx |
Physical examination |
|
|
PFS |
Progression-free survival |
|
|
PFT |
Pulmonary function test |
|
|
PGA |
Polyglandular autoimmune syndrome |
|
|
PGDE |
Pharmacologically-guided dose-escalations |
|
|
P-gp |
P-glycoprotein |
|
|
PI |
Principal investigator |
|
|
PK |
Pharmacokinetics |
|
|
Pyruvate Kinase |
||
|
PLAP |
Placenta-like alkaline phosphatase |
|
|
PLCO |
Prostate, Lung, Colorectal, & Ovarian |
|
|
PLL |
Prolymphocytic leukemia |
|
|
plt |
Platelet |
|
|
PMF |
Primary myelofibrosis |
|
|
PML |
Progressive multifocal leukoencephalopathy |
|
|
PMN |
Polymorphonuclear leukocyte |
|
|
PNA |
Pneumonia |
|
|
PNET |
Primitive neuroectodermal |
|
|
pNETs |
Pancreatic NETs |
|
|
PNETs |
Pancreatic neuroendocrine tumors |
|
|
PNH |
Paroxysmal nocturnal hemoglobinuria |
|
|
PNI |
Perineural invasion |
|
|
PO |
Oral intake |
|
|
POD |
Progression of disease |
|
|
polyA |
Polyadenylated |
|
|
POMA |
Postoperative margin assessment |
|
|
PORT |
Postoperative RT |
|
|
PPI |
Proton pump inhibitors |
|
|
Ppx |
Prophylaxis |
|
|
PR |
Partial response |
|
|
PR segment on ECG |
||
|
Pulmonary regurgitation |
||
|
PRCA |
Pure red cell aplasia |
|
|
prev |
Prevention |
|
|
PRL |
Prolactin |
|
|
PS |
Performance status |
|
|
Pressure support |
||
|
Pulmonic stenosis |
||
|
PSA |
Prostate specific antigen |
|
|
PSAV |
Prostate specific antigen velocity |
|
|
PSC |
Primary sclerosing cholangitis |
|
|
PSMA |
Prostate specific membrane antigen |
|
|
Pt |
Patient |
|
|
PT |
Prothrombin time |
|
|
PTH |
Parathyroid hormone |
|
|
PTH-rP |
Parathyroid hormone-related peptide |
|
|
PTHrp |
PTH-related protein |
|
|
PTLD |
Post-transplant lymphoproliferative disorders |
|
|
PUVA |
Psoralen plus ultraviolet A |
|
|
PV |
Portal vein |
|
|
Every bedtime |
||
|
QoL |
Quality of life |
|
|
r/i |
Rule in |
|
|
r/o |
Rule out |
|
|
RA |
Refractory anemia |
|
|
RAI |
Radioactive iodine |
|
|
RAR |
Retinoic acid receptor |
|
|
RARS |
Refractory Anemia w/ringed sideroblasts |
|
|
RAS |
Renal artery stenosis |
|
|
RB1 |
Retinoblastoma 1 |
|
|
RBC |
Red blood cell |
|
|
RBE |
Relative biologic effectiveness |
|
|
RCC |
Renal cell carcinoma |
|
|
RCMD |
Refractory cytopenia w/multilineage dysplasia |
|
|
RCT |
Randomized controlled trial |
|
|
RDW |
Red cell distribution width |
|
|
RE |
Reticuloendothelial |
|
|
RF |
Risk factor |
|
|
RFA |
Radiofrequency embolization |
|
|
RFS |
Recurrence-free survival |
|
|
RI |
Reticulocyte index |
|
|
RIC |
Reduced-intensity Conditioning |
|
|
RIT |
Radioimmunotherapy |
|
|
RMSF |
Rocky Mountain spotted fever |
|
|
ROC |
Receiver operating characteristic |
|
|
ROS |
Review of systems |
|
|
ROTI |
Related Organ or Tissue Impairment |
|
|
RP |
Radical prostatectomy |
|
|
RP |
Retroperitoneum |
|
|
RP2D |
Recommended phase 2 dose |
|
|
RR |
Relative risk/risk ratio |
|
|
RR |
Response rate |
|
|
RR |
Ribonucleotide reductase |
|
|
rrBSO |
Risk-reducing bilateral salpingo-oophorectomy |
|
|
RS |
Recurrence score |
|
|
RS |
Ringed sideroblasts |
|
|
RSV |
Respiratory syncytial virus |
|
|
RT |
Radiation therapy |
|
|
RTA |
Renal tubular acidosis |
|
|
RUQ |
Right upper quadrant |
|
|
Rx |
Therapy |
|
|
rxn |
Reaction |
|
|
s/e |
Side effect |
|
|
s/p |
Status post |
|
|
s/s |
Signs and symptoms |
|
|
SAA |
Serum amyloid A |
|
|
SABR |
Stereotactic ablative body radiotherapy |
|
|
SBE |
Subacute bacterial endocarditis |
|
|
SBP |
Spontaneous bacterial peritonitis |
|
|
SBRT |
Stereotactic body RT |
|
|
SBS |
Sequencing by synthesis |
|
|
SC |
Subcutaneous |
|
|
SCC |
Squamous cell carcinoma |
|
|
SCID |
Severe combined immunodeficiency |
|
|
SCLC |
Small cell lung cancer |
|
|
SCr |
Serum creatinine |
|
|
SCT |
Stem cell transplantation |
|
|
SD |
Stable disease |
|
|
SDH |
Succinate dehydrogenase |
|
|
Se |
Sensitivity |
|
|
SEER |
Surveillance Epidemiology and End Results |
|
|
SERD |
Selective estrogen receptor down-regulator |
|
|
SERM |
Selective estrogen receptor modulator |
|
|
sev. |
Severe |
|
|
SFLC |
Serum free light chain assay |
|
|
SIADH |
Syndrome of inappropriate antidiuretic hormone |
|
|
SIF |
Serum immunofixation |
|
|
SIRS |
Systemic inflammatory response syndrome |
|
|
SLE |
Systemic lupus erythematosus |
|
|
SLL |
Small lymphocytic lymphoma |
|
|
SMA |
Superior mesenteric artery |
|
|
SM- |
Systemic mastocytosis w/ |
|
|
AHNMD |
associated hematologic non-mast cell lineage disorder |
|
|
SMILE |
Steroid, MTX, ifosfamide, L-asparaginase, etoposide |
|
|
SMRP |
Soluble mesothelin-related peptide |
|
|
SMV |
Superior mesenteric vein |
|
|
SMX |
Sulfamethoxazole |
|
|
SNB |
Sentinel node biopsy |
|
|
SNP |
Single nucleotide polymorphisms |
|
|
SOB |
Sulphur-oxidizing bacteria |
|
|
SOM |
Self-Organizing Maps |
|
|
SOS |
Sinusoidal obstructive syndrome |
|
|
Sp |
Specificity |
|
|
SPEP |
Serum protein electrophoresis |
|
|
SPT |
Second primary tumors |
|
|
SPTCL |
Subcutaneous panniculitis-like T cell lymphoma |
|
|
SQCLC |
Squamous cell lung cancer |
|
|
SRE |
Skeletal-related event |
|
|
SRS |
Stereotactic radiosurgery |
|
|
SS |
Sézary syndrome |
|
|
SSC |
Side Scatter |
|
|
SSM |
Smoldering systemic mastocytosis |
|
|
SSRI |
Selective serotonin reuptake inhibitor |
|
|
SSS |
Surgical Staging System |
|
|
STD |
Sexually transmitted disease |
|
|
STIC |
Serous tubular intraepithelial ca |
|
|
STLI |
Subtotal lymphocyte irradiation |
|
|
STS |
Soft tissue sarcomas |
|
|
Standard uptake value |
||
|
SVC |
Superior vena cava |
|
|
sx |
Symptom(s) |
|
|
TACE |
Transarterial chemoembolization |
|
|
TACO |
Transfusion-associated circulatory overload |
|
|
TAE |
Transarterial embolization |
|
|
TAH |
Total abdominal hysterectomy |
|
|
TB |
Tuberculosis |
|
|
TBI |
Total body irradiation |
|
|
TC |
Thymic carcinoma |
|
|
TCA |
Tricyclic antidepressant |
|
|
TCR |
T cell receptors |
|
|
TdT |
Terminal deoxynucleotidyl transferase |
|
|
TEPA |
Tetraethylenepentamine |
|
|
TFTs |
Thyroid function tests |
|
|
TG |
Triglycerides |
|
|
TIA |
Transient ischemic attack |
|
|
TIBC |
Total iron binding capacity |
|
|
TIL |
Tumor infiltrating lymphocytes |
|
|
TITE-CRM |
Time to event-CRM |
|
|
TK |
Tyrosine kinase |
|
|
TKI |
Tyrosine kinase inhibitor |
|
|
TLI |
Total lymphocyte irradiation |
|
|
TLR7 |
Toll-like receptor 7 |
|
|
TLS |
Tumor lysis syndrome |
|
|
TME |
Total mesorectal excision |
|
|
TMP |
Trimethoprim |
|
|
TMPT |
Thiopurine methyltransferase |
|
|
Tn |
Troponin |
|
|
TN |
True negative/true – |
|
|
TNF |
Tumor necrosis factor |
|
|
TNM |
Tumor, node, metastasis |
|
|
tox |
Toxicity |
|
|
TP |
True positive/true + |
|
|
TPN |
Total parenteral nutrition |
|
|
Tpo |
Thrombopoietin |
|
|
TPO |
Thyroid peroxidase |
|
|
TRALI |
Transfusion-related acute lung injury |
|
|
Treg |
Regulatory T cells |
|
|
TRUS |
Transrectal ultrasound |
|
|
TS |
Thymidylate synthase |
|
|
TSC |
Tuberous sclerosis complex |
|
|
TSEB |
Total skin electron beam |
|
|
TSEBT |
Total skin electron beam therapy |
|
|
TSGs |
Tumor suppressor genes |
|
|
TSH |
Thyroid stimulating hormone |
|
|
TSS |
Toxic shock syndrome |
|
|
Transsphenoidal surgery |
||
|
TTF-1 |
Thyroid Transcription Factor-1 |
|
|
TTP |
Thrombotic thrombocytopenic purpura |
|
|
TTP |
Time to progression |
|
|
TTR |
Transthyretin |
|
|
TTTF |
Time to treatment failure |
|
|
tx |
Treatment |
|
|
U/A |
Urinalysis |
|
|
U/S |
Ultrasound |
|
|
UA |
Unstable angina |
|
|
Uric acid |
||
|
UC |
Ulcerative colitis |
|
|
UC |
Urothelial Carcinoma |
|
|
UCB |
Umbilical cord blood |
|
|
UFH |
Unfractionated heparin |
|
|
UIF |
Urine immunofixation |
|
|
UGT1A1 |
Uridine Diphosphate Glucuronosyltransferase 1A1 |
|
|
ULN |
Upper limit of normal |
|
|
UOP |
Urine output |
|
|
UPEP |
Urine protein electrophoresis |
|
|
URI |
Upper respiratory tract infection |
|
|
UROD |
Uroporphyrinogen decarboxylase |
|
|
usu |
Usually |
|
|
UTI |
Urinary tract infection |
|
|
VAC |
Vincristine + doxorubicin + cyclophosphamide |
|
|
VEGF |
Vascular endothelial growth factor |
|
|
VEGFR |
Vascular endothelial growth factor receptor |
|
|
VelP |
Vinblastine, ifosfamide, and cisplatin |
|
|
VF |
Ventricular fibrillation |
|
|
VHL |
Von hippel-lindau |
|
|
VIDE |
Vincristine + ifosfamide + doxorubicin + etoposide |
|
|
VIE |
Vincristine + doxorubicin + ifosfamide |
|
|
VOC |
Vaso-occlusive Crisis |
|
|
VOD |
Veno-occlusive disease |
|
|
VP |
Variegate porphyria |
|
|
VRE |
Vancomycin resistant enterococcus |
|
|
VSV |
Vesicular stomatitis virus |
|
|
VTE |
Venous thromboembolus |
|
|
vWD |
von Willebrand disease |
|
|
vWF |
von Willebrand factor |
|
|
VZV |
Varicella zoster virus |
|
|
w/ |
With |
|
|
w/c |
Which |
|
|
w/in |
Within |
|
|
w/o |
Without |
|
|
w/u |
Workup |
|
|
WBC |
White blood cell (count) |
|
|
WBRT |
Whole brain RT |
|
|
WHO |
World Health Organization |
|
|
wk |
Week |
|
|
WM |
Waldenström macroglobulinemia |
|
|
wt |
Weight |
|
|
WT |
Wilms tumor |
|
|
βB |
Beta-blocker |
|
|
γ |
Gamma rays |